๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

5,609 results for โ€œABโ€ Clear

  1. Suptavumab 30 mg/kg

    Regeneron UK Limited

    Respiratory Syncytial Virus Infections

    phase 3 small molecule completed

    1 trial

  2. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  3. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  4. Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)

    AstraZeneca AB

    Inadequately Controlled Asthma

    phase 3 small molecule active

    1 trial

  5. T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietoลกanai zem mฤ“les

    Lacuna Pharma Pty Ltd

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

  6. TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan

    AstraZeneca AB

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  7. TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 small molecule active

    1 trial

  8. TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  9. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  10. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobasยฎ EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  11. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 small molecule active

    1 trial

  12. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  14. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  15. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  16. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  17. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  18. TAK-875

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    4 trials

  19. TAK-875

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  20. TAK-875

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  21. TAK-875

    Takeda

    Diabetic Patients

    phase 3 small molecule completed

    1 trial

  22. TAK-875

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  23. TAMOXIFEN , EXEMESTANE , ANASTROZOLE , LETROZOLE , Verzenios 50 mg film-coated tablets

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  24. TENOFOVIR DISOPROXIL AND EMTRICITABINE , MK-8527 F1, Placebo for MK-8527, Placebo for Emtricitabine/Tenofovir Disoproxil

    Merck Sharp and Dohme

    HIV-1 prevention

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources